ERUS-DRUS20 Day 1: Virtual Robots

The EAU’s premier robotic urology event has started. Not in Düsseldorf as originally intended (and long hoped for), but as a two-day virtual event. The EAU Robotic Urology Section has years, if not decades, of experience with live transmissions of surgery from all across the world so it was well prepared for holding a virtual […]

Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter.

Men treated for localized prostate cancer by radiotherapy have often a remaining life span of 10 yr or more. Therefore, the risk for secondary malignancies should be taken into account. Plans for ten patients were evaluated which had been performed on an Oncentra® treatment planning system for a treatment with an Elekta Synergy™ linac with Agility™ […]

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and taxane.

X